Which has higher earnings and valuation, TLX or PHAR?

Pharming Group has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A Pharming Group $376.13M 2.59 $2.85M $0.16 86.06

Pharming Group (PHAR) Competitors

$13.77 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$13.77 0.00 (0.00%)

As of 07/2/2026 06:12 PM Eastern

Compare

PHAR vs. TLX, RCUS, GPCR, CPRX, and DYN

Should you buy Pharming Group stock or one of its competitors? MarketBeat compares Pharming Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharming Group include Telix Pharmaceuticals (TLX), Arcus Biosciences (RCUS), Structure Therapeutics (GPCR), Catalyst Pharmaceuticals (CPRX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Pharming Group compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Telix Pharmaceuticals presently has a consensus target price of $21.13, suggesting a potential upside of 77.97%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 178.38%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Telix Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Pharming Group has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A
Pharming Group	$376.13M	2.59	$2.85M	$0.16	86.06

Pharming Group has a net margin of 3.30% compared to Telix Pharmaceuticals' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Pharming Group	3.30%	4.64%	2.55%

0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.85 beat Telix Pharmaceuticals' score of -0.32 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Telix Pharmaceuticals	Neutral
Pharming Group	Very Positive

Summary

Pharming Group beats Telix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Pharming Group has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.49	-$353M	-$3.18	N/A
Pharming Group	$376.13M	2.59	$2.85M	$0.16	86.06

Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, Arcus Biosciences had 4 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Arcus Biosciences and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.85 beat Arcus Biosciences' score of 0.06 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcus Biosciences	Neutral
Pharming Group	Very Positive

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcus Biosciences presently has a consensus target price of $35.10, indicating a potential upside of 15.38%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 178.38%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to Arcus Biosciences' net margin of -156.36%. Pharming Group's return on equity of 4.64% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Pharming Group	3.30%	4.64%	2.55%

Summary

Pharming Group beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Structure Therapeutics had 2 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.85 beat Structure Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Structure Therapeutics	Neutral
Pharming Group	Very Positive

Structure Therapeutics presently has a consensus target price of $110.55, suggesting a potential upside of 106.82%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 178.38%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Pharming Group	$376.13M	2.59	$2.85M	$0.16	86.06

Structure Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Pharming Group has a net margin of 3.30% compared to Structure Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Pharming Group	3.30%	4.64%	2.55%

Summary

Pharming Group beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals presently has a consensus price target of $32.00, indicating a potential upside of 1.75%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 178.38%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Pharming Group's net margin of 3.30%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Pharming Group	3.30%	4.64%	2.55%

Catalyst Pharmaceuticals has higher revenue and earnings than Pharming Group. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.54	$214.33M	$1.74	18.07
Pharming Group	$376.13M	2.59	$2.85M	$0.16	86.06

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

In the previous week, Catalyst Pharmaceuticals had 3 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for Catalyst Pharmaceuticals and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.85 beat Catalyst Pharmaceuticals' score of 0.25 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Pharming Group	Very Positive

Summary

Catalyst Pharmaceuticals beats Pharming Group on 13 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Pharming Group has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Pharming Group	$376.13M	2.59	$2.85M	$0.16	86.06

In the previous week, Dyne Therapeutics had 9 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Dyne Therapeutics and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.85 beat Dyne Therapeutics' score of 0.28 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyne Therapeutics	Neutral
Pharming Group	Very Positive

Dyne Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Dyne Therapeutics currently has a consensus price target of $34.17, suggesting a potential upside of 48.10%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 178.38%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharming Group has a net margin of 3.30% compared to Dyne Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Pharming Group	3.30%	4.64%	2.55%

Summary

Pharming Group beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$972.51M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	86.07	21.61	28.02	24.70
Price / Sales	2.59	340.19	540.37	99.49
Price / Cash	68.66	147.12	49.26	57.09
Price / Book	3.49	8.66	10.96	6.46
Net Income	$2.85M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.00%	3.39%	2.12%	1.69%
1 Month Performance	9.16%	10.81%	5.25%	3.81%
1 Year Performance	32.66%	62.61%	33.29%	23.90%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	3.986 of 5 stars	$13.77 flat	$38.33 +178.4%	+32.7%	$972.51M	$376.13M	86.07	280	Positive News
TLX Telix Pharmaceuticals	4.5133 of 5 stars	$11.51 +1.9%	$21.13 +83.5%	-26.4%	$3.92B	$803.79M	N/A	1,184	Gap Up
RCUS Arcus Biosciences	2.1928 of 5 stars	$30.95 -0.4%	$35.10 +13.4%	+259.4%	$3.91B	$247M	N/A	500	Gap Down
GPCR Structure Therapeutics	1.8015 of 5 stars	$54.25 +5.0%	$110.55 +103.8%	+159.2%	$3.86B	N/A	N/A	136	Gap Down
CPRX Catalyst Pharmaceuticals	3.408 of 5 stars	$31.45 0.0%	$32.00 +1.8%	+45.3%	$3.85B	$588.99M	18.07	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. TLX, RCUS, GPCR, CPRX, and DYN

How does Pharming Group compare to Telix Pharmaceuticals?

Summary

How does Pharming Group compare to Arcus Biosciences?

Summary

How does Pharming Group compare to Structure Therapeutics?

Summary

How does Pharming Group compare to Catalyst Pharmaceuticals?

Summary

How does Pharming Group compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. TLX, RCUS, GPCR, CPRX, and DYN

How does Pharming Group compare to Telix Pharmaceuticals?

Do analysts rate TLX or PHAR?

Which has more volatility & risk, TLX or PHAR?

Which has higher earnings and valuation, TLX or PHAR?

Is TLX or PHAR more profitable?

Do institutionals & insiders hold more shares of TLX or PHAR?

Does the media prefer TLX or PHAR?

Summary

How does Pharming Group compare to Arcus Biosciences?

Which has higher valuation & earnings, RCUS or PHAR?

Which has more risk and volatility, RCUS or PHAR?

Does the media refer more to RCUS or PHAR?

Do insiders and institutionals hold more shares of RCUS or PHAR?

Do analysts prefer RCUS or PHAR?

Is RCUS or PHAR more profitable?

Summary

How does Pharming Group compare to Structure Therapeutics?

Does the media favor GPCR or PHAR?

Do analysts rate GPCR or PHAR?

Do insiders & institutionals believe in GPCR or PHAR?

Which has preferable valuation and earnings, GPCR or PHAR?

Which has more risk and volatility, GPCR or PHAR?

Is GPCR or PHAR more profitable?

Summary

How does Pharming Group compare to Catalyst Pharmaceuticals?

Do institutionals & insiders believe in CPRX or PHAR?

Do analysts rate CPRX or PHAR?

Is CPRX or PHAR more profitable?

Which has stronger valuation & earnings, CPRX or PHAR?

Which has more risk and volatility, CPRX or PHAR?

Does the media favor CPRX or PHAR?

Summary

How does Pharming Group compare to Dyne Therapeutics?

Which has higher valuation and earnings, DYN or PHAR?

Does the media refer more to DYN or PHAR?

Which has more risk and volatility, DYN or PHAR?

Do analysts prefer DYN or PHAR?

Do institutionals and insiders hold more shares of DYN or PHAR?

Is DYN or PHAR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools